Pages that link to "Q50884327"

The following pages link to The health burdens of Parkinson's disease. (Q50884327):

Displaying 50 items.

• The economic impact of Parkinson's disease (Q22251241) (← links)
• Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy (Q24793543) (← links)
• Societal costs of exposure to toxic substances: economic and health costs of four case studies that are candidates for environmental causation (Q24814856) (← links)
• Disability Rating Scales in Parkinson's Disease: Critique and Recommendations (Q30250276) (← links)
• Rehabilitation for Parkinson's disease: a systematic review of available evidence (Q31104672) (← links)
• Cost effectiveness of pramipexole in Parkinson's disease in the US. (Q33645616) (← links)
• Health-related quality-of-life measurement in patients with Parkinson's disease (Q33648357) (← links)
• Maximizing the benefit of pharmacotherapy in Parkinson's disease (Q33821348) (← links)
• Efficacy and safety of nighttime dosing of antihypertensives: review of the literature and design of a pragmatic clinical trial. (Q33881994) (← links)
• Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions (Q33929699) (← links)
• Economic and health-related quality of life considerations of new therapies in Parkinson's disease (Q34363332) (← links)
• Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias (Q34458647) (← links)
• The relative health related quality of life of veterans with Parkinson's disease. (Q35471560) (← links)
• Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles (Q35473731) (← links)
• The generic 15D instrument is valid and feasible for measuring health related quality of life in Parkinson's disease (Q35482058) (← links)
• Health related quality of life in Parkinson's disease: a prospective longitudinal study (Q35572190) (← links)
• Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease (Q36142291) (← links)
• The effect of deep brain stimulation on quality of life in movement disorders (Q36233666) (← links)
• Clinical predictors of frequent patient telephone calls in Parkinson's disease. (Q36728875) (← links)
• A Cross-Sectional Study on Socioeconomic Systems Supporting Outpatients With Parkinson's Disease in Japan. (Q36731574) (← links)
• Loss of ability to work and ability to live independently in Parkinson’s disease (Q37687797) (← links)
• The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal. (Q37891050) (← links)
• Health-related quality-of-life scales in Parkinson's disease: critique and recommendations (Q37898591) (← links)
• Patient diaries as a clinical endpoint in Parkinson's disease clinical trials. (Q37954392) (← links)
• Potential of APDM mobility lab for the monitoring of the progression of Parkinson's disease (Q38731344) (← links)
• Drug and treatment costs in Parkinson's disease patients in Sweden. (Q39763335) (← links)
• Social support for physical activity and perceptions of control in early Parkinson's disease (Q39975732) (← links)
• Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. (Q40368066) (← links)
• The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis (Q40848018) (← links)
• Attitudes to brain donation for Parkinson's research and how to ask: a qualitative study with suggested guidelines for practice (Q43636014) (← links)
• Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan (Q43763638) (← links)
• Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States (Q44079405) (← links)
• The economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset (Q44768295) (← links)
• The current and projected economic burden of Parkinson's disease in the United States (Q44988421) (← links)
• Association between neurological disorders, functioning, and mortality in the elderly. (Q45909189) (← links)
• A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson’s disease in the UK (Q45913552) (← links)
• Direct economic impact of Parkinson's disease: A research survey in the United Kingdom (Q47576690) (← links)
• Cost-effectiveness of subthalmic nucleus deep brain stimulation for the treatment of advanced Parkinson disease in Hong Kong: a prospective study. (Q48572816) (← links)
• Insomnia and depressive symptoms in patients with Parkinson's disease. Relationship to health-related quality of life. An interview study of patients living at home (Q48700487) (← links)
• Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries (Q50770517) (← links)
• Factors impacting on quality of life in Parkinson's disease: results from an international survey (Q51055467) (← links)
• Linking clinical variables to health-related quality of life in Parkinson's disease (Q51956514) (← links)
• The influence of fatigue on health-related quality of life in patients with Parkinson's disease. (Q52024029) (← links)
• Economic burden and quality of life impairment increase with severity of PD. (Q53397739) (← links)
• The quality of life in Parkinson's disease. (Q53524833) (← links)
• Impaired Quality of Life and Need for Palliative Care in a German Cohort of Advanced Parkinson's Disease Patients. (Q55176226) (← links)
• Modulatory Effects of Levodopa on Cerebellar Connectivity in Parkinson's Disease (Q57293818) (← links)
• Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease (Q57991425) (← links)
• Longitudinal evaluation of economic and physical impact of Parkinson's disease (Q74265308) (← links)
• [Prospective study of the direct and indirect costs of idiopathic Parkinson's disease] (Q79145417) (← links)